Clinical trials: Neoplasm, Plasma Cell
Multiple Myeloma
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
This phase III randomized trial compares three different peripheral stem cell mobilization regimens for patients with multiple myeloma who have received primary induction therapy or other therapies.
- Trial name
- NCT01146834
- Testing
- bortezomib (Velcade), cyclophosphamide, G-CSF
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Weill Medical College of Cornell University
Myeloproliferative Disorders, Leukemia
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00827099
- Testing
- anti-thymocyte globulin, fludarabine phosphate, Melphalan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northside Hospital, Inc.
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma
B-Cell Hematologic Malignancy Vaccination Registry
The goal of this study is to develop a vaccination registry system for Aurora Health Care patients newly diagnosed with MM and other B-Cell Hematologic Malignancies in order to prospectively characterize vaccination history and…
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Waldenstrom Macroglobulinemia, Lymphocytosis
- Trial name
- HMvax-Regist (NCT02298816)
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
The purpose of this study is to evaluate time to progression, overall survival, response rate and safety for the two open-label treatment groups; DOXIL/CAELYX in combination with VELCADE vs. VELCADE monotherapy.
- Trial name
- NCT00103506
- Testing
- Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX)
- Where
- 108 sites in United States, Argentina and 15 more
- Volunteers
- 646 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects
This is a single-centre, single ascending dose (SAD) pilot study designed to evaluate the safety, tolerability, including local tolerability, and pharmacokinetics (PK) of NEX-20A (lenalidomide) after the administration of a…
- Trial name
- NCT05643248
- Testing
- NEX-20A
- Where
- Sweden
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Nanexa AB
Lymphoma, Multiple Myeloma
CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig
This is a prospective, interventional study administering 2 doses of the experimental vaccine (CMV-MVA Triplex) to 20 evaluable patients (10 CMV-seropositive and 10 seronegative) undergoing autologous hematopoietic cell…
- Trial name
- NCT03383055
- Testing
- CMV-MVA Triplex Vaccine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
This phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor (CAR) T therapy after chemotherapy in treating patients who have CS1 positive multiple myeloma that has come back (relapsed) or does not…
- Trial name
- NCT03710421
- Testing
- CS1-CAR T Therapy, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Leukemia, Lymphoma
A Phase II Study of Umbilical Cord Blood Transplantation
This study is designed to determine whether Umbilical Cord Transplantation (UCB) can be substituted for adult bone marrow cells in the standard stem cell transplant regimens used at this hospital for subjects who do not have stem…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Aplastic Anemia
- Trial name
- NCT00676806
- Testing
- Umbilical Cord Blood After Myeloablative Conditioning, Umbilical Cord Blood After Reduced-Intensity Conditioning
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Tufts Medical Center
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
This phase II trial compares the effect of the combination of daratumumab-hyaluronidase (daratumumab) and teclistamab to the usual treatment of daratumumab, pomalidomide, dexamethasone or daratumumab, carfilzomib and…
- Trial name
- NCT06948084
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib
- Where
- 31 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma
A total of 40 Multiple Myeloma (MM) patients at clinical relapse who progressed during Proteasome Inhibitors (PIs) or Immunomodulating Drugs (IMiDs)-based therapies and who are assigned to antiCD38-based salvage treatments, will…
- Trial name
- NCT03848676
- Testing
- Evaluation of patients resistance to immunotherapies in Multiple Myeloma
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of Turin, Italy
Plasma Cell Myeloma
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies how well ixazomib citrate, lenalidomide, dexamethasone, and daratumumab work in treating patients with newly diagnosed multiple myeloma.
- Trial name
- NCT03012880
- Testing
- Daratumumab, Dexamethasone, Ixazomib Citrate
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
The primary objective of this Phase Ib/II trial is to study the safety and tolerability of the combination of selinexor, carfilzomib, isatuximab-OBDS (on body delivery system) and dexamethasone in patients with relapsed or…
- Trial name
- NCT07479979
- Testing
- Selinexor, Carfilzomib, Isatuximab
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Natalie Callander
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma
This clinical trial evaluates whether prehabilitation with aerobic and resistance exercise improves physical fitness and quality of life outcomes in older patients planning to undergo chimeric antigen receptor (CAR)-T therapy for…
- Trial name
- NCT07045727
- Testing
- Accelerometry, Aerobic Exercise, Biospecimen Collection
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Mature B-Cell Neoplasm
Liquid Biopsy in Mature B-cell Tumors
The study aims at assessing whether cell free DNA genotyping can improve the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive…
- Trial name
- NCT03280394
- Testing
- Liquid Biopsy
- Where
- Switzerland
- Volunteers
- 444 people
- Sponsor
- Oncology Institute of Southern Switzerland
Carcinoma, Non-Small-Cell Lung
Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer
Genetic rearrangements in the Anaplastic Lymphoma Kinase (ALK) gene result in the creation of a variety of oncogenic fusion proteins that drive malignancy in a subset of non-small cell lung cancers (NSCLC) patients.
- Trial name
- NCT02718651
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- University of Aarhus
Multiple Myeloma
Study of BCMA CAR-T in Multiple Myeloma
The purpose of this study is to infusion BCMA CAR-T cells to the patients with relapsed and refractory multiple myeloma(MM), to assess the safety and feasibility of this strategy.
- Trial name
- NCT03322735
- Testing
- Fludarabine, Cyclophosphamide, BCMA CAR-T
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Henan Cancer Hospital
Indolent Non-Hodgkin's Lymphomas
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
The primary objective of this study is to evaluate the effect of the addition of idelalisib to rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Trial name
- Yosemite (NCT01732913)
- Testing
- Rituximab, Idelalisib
- Where
- 103 sites in United States, Australia and 17 more
- Volunteers
- 295 people
- Sponsor
- Gilead Sciences
AL Amyloidosis
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
This phase II trial compares shorter-duration versus longer-duration maintenance therapy with daratumumab for improving survival in patients who have received initial treatment with daratumumab for light chain (AL) amyloidosis.
- Trial name
- NCT05898646
- Testing
- Bone Marrow Aspiration, Daratumumab, Echocardiography Test
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma
- Trial name
- NCT01890486
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma, Myeloma
FT576 in Subjects With Multiple Myeloma
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
- Trial name
- NCT05182073
- Testing
- FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine
- Where
- 14 sites in United States
- Volunteers
- 31 people
- Sponsor
- Fate Therapeutics